GlassScriptPhysician profile
Nicholas J Farrell
NPI 1821291477
$2,009.78
in general payments reported to CMS, 2019-2025
38 companies · $1,095 in 2025
The $1,095 reported for 2025 was more than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $11.92 · 2022: $10.85 · 2023: $165 · 2024: $727 · 2025: $1,095.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,987.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,987.01 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $242.92 | 2023-2025 | |
| Astrazeneca Pharmaceuticals LP | $200.24 | 2024-2025 | Imfinzi, Calquence |
| Glaxosmithkline, LLC. | $182.69 | 2024-2025 | Zejula, Jemperli, Blenrep |
| Merck Sharp & Dohme LLC | $177.99 | 2022-2025 | Keytruda, Keytruda Qlex, Welireg |
| Daiichi Sankyo INC. | $134.14 | 2023-2025 | Enhertu, Injectafer |
| Takeda Pharmaceuticals U.S.A., INC. | $111.27 | 2024-2025 | Fruzaqla, Ninlaro |
| Incyte Corporation | $109.75 | 2023-2025 | Jakafi, Monjuvi |
| Abbvie INC. | $97.16 | 2025 | |
| Eisai INC. | $80.72 | 2024-2025 | |
| Pfizer INC. | $63.33 | 2024-2025 | |
| E.R. Squibb & Sons, L.L.C. | $62.03 | 2024-2025 | Opdivo, Augtyro |
| Alexion Pharmaceuticals, INC. | $51.36 | 2024 | Ultomiris |
| Taiho Oncology, INC. | $45.06 | 2024-2025 | |
| Janssen Biotech, INC. | $42.75 | 2023-2025 | Talvey, Akeega, Erleada |
| Aveo Pharmaceuticals, INC. | $36.85 | 2025 |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Celgene Corporation | $32.26 | 2024 | Pomalyst |
| Pharmaessentia USA Corporation | $32.14 | 2025 | Besremi |
| Gilead Sciences, INC. | $32.13 | 2021-2024 | |
| Bayer Healthcare Pharmaceuticals INC. | $31.60 | 2025 | |
| Beigene USA, INC. | $26.56 | 2025 | Tevimbra |
| Exelixis INC. | $25.01 | 2023 | Cabometyx |
| Legend Biotech USA INC. | $24.46 | 2025 | Carvykti |
| Array Biopharma INC | $24.46 | 2025 | Mektovi, Braftovi, Lorbrena |
| Regeneron Healthcare Solutions, INC. | $23.32 | 2025 | Libtayo |
| Genentech USA, INC. | $21.91 | 2024 | Gazyva, Venclexta |
| Stemline Therapeutics INC. | $19.82 | 2025 | Orserdu |
| Lilly USA, LLC | $19.44 | 2024 | Jaypirca, Retevmo, Verzenio |
| Puma Biotechnology, INC. | $16.18 | 2025 | |
| Astellas Pharma US INC | $15.03 | 2025 | Vyloy |
| Iovance Biotherapeutics, INC. | $13.66 | 2025 | Amtagvi |
| Alnylam Pharmaceuticals INC. | $13.54 | 2025 | Givlaari |
7 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Nicholas Farrell listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.